The FTO Mediated N6-Methyladenosine Modification of DDIT4 Regulation with Tumorigenesis and Metastasis in Prostate Cancer

Overview

Journal Research (Wash D C)

Specialty Biology

Date 2024 Feb 22

PMID 38384328

Authors

Yue Zhao

Xin Hu

Haoran Yu

Huimin Sun

Lei Zhang

Chen Shao

Affiliations

Soon will be listed here.

Abstract

The progression of numerous malignancies has been linked to N6-methyladenosine (m6A) alteration. However, the opposite trend of m6A levels in the development and metastasis of cancer has not been reported. This study aimed to evaluate the biological function and mechanism of fat mass and obesity-associated protein (FTO) in regulating m6A modification in prostate cancer development and epithelial-mesenchymal transition (EMT). An EMT model of LNCaP and PC-3 cells was established with transforming growth factor-β treatment, and FTO knockout cell line was established in prostate cancer cells using the CRISPR/Cas9 gene editing technology. The level of m6A modification in tumor tissues was higher than that in normal prostate tissues; m6A levels were decreased after EMT. FTO deletion increased m6A expression and enhanced PC-3 cell motility, invasion, and EMT both in vitro and in vivo. RNA sequencing and functional investigations suggested that DDIT4, a novel EMT target gene, plays a role in m6A-regulated EMT, which was recognized and stabilized by the m6A effector IGF2BP2/3. Decreased FTO expression was an independent indicator of worse survival, and the level of DDIT4 was considerably elevated in patients with bone metastasis. Thus, this study revealed that the m6A demethylase FTO can play different roles in prostate cancer as a regulator of EMT and an inhibitor of m6A modification. Moreover, DDIT4 can be suggested as a possible biomarker for prostate cancer metastasis prediction.

Citing Articles

The role of N(6)-methyladenosine (m6a) modification in cancer: recent advances and future directions.

Xie X, Fang Z, Zhang H, Wang Z, Li J, Jia Y EXCLI J. 2025; 24:113-150.

PMID: 39967906 PMC: 11830918. DOI: 10.17179/excli2024-7935.

METTL14-mediated mA modification of DDIT4 promotes its mRNA stability in aging-related idiopathic pulmonary fibrosis.

Li D, Qian L, Du Y, Liu L, Sun Z, Han Y Epigenetics. 2025; 20(1):2462898.

PMID: 39916577 PMC: 11810098. DOI: 10.1080/15592294.2025.2462898.

YTHDF2 promotes anaplastic thyroid cancer progression by activating the DDIT4/AKT/mTOR signaling pathway.

Dai B, Xu L, Rong S, Song M, Lan Z, Chen W Biol Direct. 2024; 19(1):122.

PMID: 39593172 PMC: 11600618. DOI: 10.1186/s13062-024-00566-y.

Stabilization of RRBP1 mRNA via an mA-dependent manner in prostate cancer constitutes a therapeutic vulnerability amenable to small-peptide inhibition of METTL3.

Feng Y, Li Z, Zhu J, Zou C, Tian Y, Xiong J Cell Mol Life Sci. 2024; 81(1):414.

PMID: 39367907 PMC: 11455910. DOI: 10.1007/s00018-024-05418-6.

Machine learning-based cell death marker for predicting prognosis and identifying tumor immune microenvironment in prostate cancer.

Gao F, Huang Y, Yang M, He L, Yu Q, Cai Y Heliyon. 2024; 10(18):e37554.

PMID: 39309810 PMC: 11414577. DOI: 10.1016/j.heliyon.2024.e37554.

References

Zhu M, Kyprianou N . Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J. 2009; 24(3):769-77. PMC: 2830130. DOI: 10.1096/fj.09-136994. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Thuault S, Tan E, Peinado H, Cano A, Heldin C, Moustakas A . HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem. 2008; 283(48):33437-46. PMC: 2662269. DOI: 10.1074/jbc.M802016200. View

Fu Y, Dominissini D, Rechavi G, He C . Gene expression regulation mediated through reversible m⁶A RNA methylation. Nat Rev Genet. 2014; 15(5):293-306. DOI: 10.1038/nrg3724. View

Tan Z, Shi S, Xu J, Liu X, Lei Y, Zhang B . RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an mA-YTHDF2-dependent manner. Oncogene. 2022; 41(20):2860-2872. PMC: 9106577. DOI: 10.1038/s41388-022-02306-w. View

Cheng L, Yang F, Tang L, Qian L, Chen X, Guan F . Electrochemical Evaluation of Tumor Development via Cellular Interface Supported CRISPR/Cas Trans-Cleavage. Research (Wash D C). 2022; 2022:9826484. PMC: 9011167. DOI: 10.34133/2022/9826484. View

Niu Y, Lin Z, Wan A, Chen H, Liang H, Sun L . RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. Mol Cancer. 2019; 18(1):46. PMC: 6437932. DOI: 10.1186/s12943-019-1004-4. View

Dicken H, Hensley P, Kyprianou N . Prostate tumor neuroendocrine differentiation via EMT: The road less traveled. Asian J Urol. 2019; 6(1):82-90. PMC: 6363600. DOI: 10.1016/j.ajur.2018.11.001. View

Kensler K, Pernar C, Mahal B, Nguyen P, Trinh Q, Kibel A . Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. J Natl Cancer Inst. 2020; 113(6):719-726. PMC: 8168268. DOI: 10.1093/jnci/djaa171. View

10.

Li Z, Weng H, Su R, Weng X, Zuo Z, Li C . FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N-Methyladenosine RNA Demethylase. Cancer Cell. 2016; 31(1):127-141. PMC: 5234852. DOI: 10.1016/j.ccell.2016.11.017. View

11.

Shi H, Wei J, He C . Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers. Mol Cell. 2019; 74(4):640-650. PMC: 6527355. DOI: 10.1016/j.molcel.2019.04.025. View

12.

Zhang Y, Weinberg R . Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med. 2018; 12(4):361-373. PMC: 6186394. DOI: 10.1007/s11684-018-0656-6. View

13.

Heinlein C, Chang C . Androgen receptor in prostate cancer. Endocr Rev. 2004; 25(2):276-308. DOI: 10.1210/er.2002-0032. View

14.

Zhu K, Li Y, Xu Y . The FTO mA demethylase inhibits the invasion and migration of prostate cancer cells by regulating total mA levels. Life Sci. 2021; 271:119180. DOI: 10.1016/j.lfs.2021.119180. View

15.

Smith B, Odero-Marah V . The role of Snail in prostate cancer. Cell Adh Migr. 2012; 6(5):433-41. PMC: 3496681. DOI: 10.4161/cam.21687. View

16.

Pan D, Dong J, Zhang Y, Gao X . Tuberous sclerosis complex: from Drosophila to human disease. Trends Cell Biol. 2004; 14(2):78-85. DOI: 10.1016/j.tcb.2003.12.006. View

17.

Bierie B, Moses H . TGF-beta and cancer. Cytokine Growth Factor Rev. 2005; 17(1-2):29-40. DOI: 10.1016/j.cytogfr.2005.09.006. View

18.

Schwarzer R, Tondera D, Arnold W, Giese K, Klippel A, Kaufmann J . REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene. 2004; 24(7):1138-49. DOI: 10.1038/sj.onc.1208236. View

19.

Li X, Zhang P, Yin Z, Xu F, Yang Z, Jin J . Caspase-1 and Gasdermin D Afford the Optimal Targets with Distinct Switching Strategies in NLRP1b Inflammasome-Induced Cell Death. Research (Wash D C). 2022; 2022:9838341. PMC: 9343085. DOI: 10.34133/2022/9838341. View

20.

Zhao Y, Sun H, Zheng J, Shao C . Analysis of RNA mA methylation regulators and tumour immune cell infiltration characterization in prostate cancer. Artif Cells Nanomed Biotechnol. 2021; 49(1):407-435. DOI: 10.1080/21691401.2021.1912759. View